Clinicogenomic Characterization of Primary Sclerosing Cholangitis–Associated Biliary Tract Cancers
Lists
Only you see this
Abstract
Immunotherapy in PSC-associated BTCs seemed safe, with a potential signal of effectiveness. Given the sample size and retrospective design, these results are hypothesis-generating. Together, these results demonstrate the unique biology underlying PSC-associated BTCs, highlighting the need for prospective trials and the development of specialized treatment strategies.
BibTeX
@inproceedings{wang2025clinicogenomic,
author = {Xin Wang and Jaime Haro-Silerio and Felix E.G. Beaudry and Ayelet Borgida and Farnoosh Abbas‐Aghababazadeh and Nasim Bondar. Sahebi and Michael Wang and Daniel P. Fox and Mohamed Nuh and Monica Hsiang and Deepak Bhamidipati and Hyunseon C. Kang and Veronica Cox and Ethan B. Ludmir and Eugene J. Koay and Lawrence N. Kwong and Kimana Quentin and Deyali Chatterjee and Yun Shin Chun and Hop S. Tran Cao and Funda Meric‐Bernstam and Ian Hu and Anna Dodd and Oumaima Hamza and Maggie Hildebrand and Roxana Bucur and Gideon M. Hirschfield and Arndt Vogel and Grainne M. O’Kane and Steven Gallinger and Benjamin Haibe‐Kains and Faiyaz Notta and Gonzalo Sapisochín and Jennifer J. Knox and Milind Javle and Sunyoung S. Lee and Robert C. Grant},
title = {{Clinicogenomic Characterization of Primary Sclerosing Cholangitis–Associated Biliary Tract Cancers}},
booktitle = {Clinical},
year = {2025},
doi = {10.1158/1078-0432.ccr-25-1834},
}Loading related content...